Impact of amino acid substitutions in hepatitis C virus genotype 1b core region on liver steatosis and glucose tolerance in non-cirrhotic patients without overt diabetes

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 5, 2011, Pages 836-842

  Sumida, Yoshio ^a   Kanemasa, Kazuyuki ^a   Hara, Tasuku ^a   Inada, Yutaka ^a   Sakai, Kyoko ^a   Imai, Shunsuke ^a   Yoshida, Naohisa ^b   Yasui, Kohichiroh ^b   Itoh, Yoshito ^b   Okanoue, Takeshi ^c   Yoshikawa, Toshikazu ^b  

^a Nara City Hospital   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c Saiseikai Imperial Gift Foundation Inc Saiseikai Suita Hospital   (Japan)

Author keywords

Glucose tolerance; Hepatitis C virus; Insulin resistance; Steatosis

Indexed keywords

FERRITIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; INSULIN; VIRUS PROTEIN;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; FATTY LIVER; FEMALE; FERRITIN BLOOD LEVEL; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; UNIVARIATE ANALYSIS; VIRUS CORE; VIRUS GENE; VIRUS LOAD;

EID: 79954527881     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06568.x     Document Type: Article

References (46)

1. Cross TJ, Rashid MM, Berry PA, Harrison PM. The importance of steatosis in chronic hepatitis C infection and its management: a review. Hepatol. Res. 2010; 40: 237-47.
2. Westin J, Nordlinder H, Lagging M etal. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J. Hepatol. 2002; 37: 837-42.
3. Fujie H, Yotsuyanagi H, Moriya K etal. Steatosis and intrahepatic hepatitis C virus in chronic hepatitis. J. Med. Virol. 1999; 59: 141-5.
4. Lonardo A, Adinolfi LE, Loria P etal. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004; 126: 586-97.
5. Sumida Y, Kanemasa K, Fukumoto K etal. Correlation of hepatic steatosis with body mass index, serum ferritin level and hepatic fibrosis in Japanese patients with chronic hepatitis C. Hepatol. Res. 2007; 37: 263-9.
6. Mason AL, Lau JY, Hoang N etal. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29: 328-33.
7. Caronia S, Taylor K, Pagliaro L etal. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 30: 1059-63.
8. Mehta SH, Brancati FL, Sulkowski MS etal. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann. Intern. Med. 2000; 133: 592-9.
9. Shintani Y, Fujie H, Miyoshi H etal. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126: 840-8.
10. Aytug S, Reich D, Sapiro LE etal. Impaired IRS-1/PI3-kinease signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology 2003; 38: 1384-92.
11. Kawaguchi T, Yoshida T, Harada M etal. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am. J. Pathol. 2004; 165: 1499-508.
12. Koike K. Hepatitis C virus infection can present with metabolic disease by inducing insulin resistance. Intervirology 2006; 49: 51-7.
13. Hui JM, Sud A, Farrell GC etal. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003; 125: 1695-704.
14. Patton HM, Patel K, Behling C etal. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J. Hepatol. 2004; 40: 484-90.
15. Asselah T, Rubbia-Brandt L, Marcellin M, Negro F. Steatosis in chronic hepatitis C: why does it really matter? Gut 2006; 55: 123-30.
16. Romero-Gomez M, Del Mar Viloria M, Andrade RJ etal. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 12: 636-41.
17. D'Souza R, Sabin CA, Foster GR. Insulin resistance plays a role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am. J. Gastroenterol. 2005; 100: 1509-15.
18. Soresi M, Tripi S, Franco V etal. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis. Liver Int. 2006; 26: 1119-25.
19. Akuta N, Suzuki F, Sezaki H etal. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005; 48: 372-80.
20. Donlin MJ, Cannon NA, Yao E etal. Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J. Virol. 2007; 81: 8211-24.
21. Okanoue T, Itoh Y, Hashimoto H etal. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J. Gastroenterol. 2009; 44: 952-63.
22. Akuta N, Suzuki F, Hirakawa M etal. Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus. J. Med. Virol. 2009; 81: 1032-9.
23. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 1998; 15: 539-53.
24. Seltzer HS, Allen EW, Herron AL Jr, Brennan MT. Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J. Clin. Invest. 1967; 46: 323-35.
25. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing. Comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-70.
26. Akuta N, Suzuki F, Kawamura Y etal. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1a: amino acid substitutions in the core region and low-density lipoprotein cholesterol level. J. Hepatol. 2007; 46: 403-10.
27. Enomoto N, Sakuma I, Asahina Y etal. Mutations in the nonstructural protein 5 A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N. Engl. J. Med. 1996; 334: 77-81.
28. Kato N, Hijikata M, Ootsuyama Y etal. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc. Natl. Acad. Sci. U.S.A. 1990; 87: 9524-8.
29. Ichida F, Tsuji T, Omata M etal. New Inuyama classification; new criteria for histological assessment of chronic hepatitis. Int. Hepatol. Commun. 1996; 6: 112-9.
30. Knodell RG, Ishak KG, Bilack WC etal. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
31. Kleiner DE, Brunt EM, Van Natta M etal. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
32. Yasui K, Harano Y, Mitsuyoshi H etal. Steatosis and hepatic expression of genes regulating lipid metabolism in Japanese patients infected with hepatitis C virus. J. Gastroenterol. 2010; 45: 95-104.
33. Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology 2005; 42: 5-13.
34. Perlemuter G, Sabile A, Letteron P etal. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J. 2002; 16: 185-94.
35. Moriishi K, Mochizuki R, Moriya K etal. Critical role of PA28g in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. Proc. Natl. Acad. Sci. U.S.A. 2007; 104: 1661-6.
36. Jackel-Cram C, Babiuk LA, Liu Q. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. J. Hepatol. 2007; 46: 999-1008.
37. Jhaveri R, McHutchison J, Patel K etal. Specific polymorphisms in hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation. J. Infect. Dis. 2008; 197: 283-91.
38. Negro F. Hepatitis C virus-induced steatosis: an overview. Dig. Dis. 2010; 28: 294-9.
39. Tachi Y, Katano Y, Honda T etal. Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C. Liver Int. 2010; 30: 554-9.
40. Fukuhara T, Takeishi K, Toshima T etal. Impact of amino acid substitutions in the core region of HCV on multistep hepatocarcinogenesis. Hepatol. Res. 2010; 40: 171-8.
41. Soonthornpun S, Setasuban W, Thamprasit A etal. Novel insulin sensitivity index derived from oral glucose tolerance test. J. Clin. Endocrinol. Metab. 2003; 88: 1019-23.
42. Abdul-Ghani MA, Matsuda M, Balas B, DeFronzo RA. Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. Diabetes Care 2007; 30: 89-94.
43. Kanauchi M, Nakajima M, Saito Y, Kanauchi K. Pancreatic beta-cell function and insulin sensitivity in Japanese subjects with impaired glucose tolerance and newly diagnosed type 2 diabetes mellitus. Metabolism 2003; 52: 476-81.
44. Fartoux L, Poujol-Robert A, Guéchot J etal. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005; 54: 1003-8.
45. Denechaud PD, Dentin R, Girard J, Postic C. Role of ChREBP in hepatic steatosis and insulin resistance. FEBS Lett. 2008; 582: 68-73.
46. Sumida Y, Kanemasa K, Hara T etal. Amino acid substitutions in the hepatitis C virus genotype1b core region are the most important predictors of liver steatosis in non-cirrhotic patients without overt diabetes independent of glucose intolerance. Hepatology 2010; 50 (Suppl): 744A.